Freenome

Freenome is a high-growth biotech company developing next-generation blood tests to detect cancer in its earliest, most treatable stages. Founded in 2014 and headquartered in Brisbane, California, Freenome uses a multiomics platform that analyzes genomic, epigenomic, and proteomic biomarkers—including tumor-derived cell-free DNA—combined with machine learning to produce actionable cancer screening results from a standard blood draw. The company's lead program targets colorectal cancer (PREEMPT CRC Study) with additional programs in lung and other cancers. In 2025, Freenome entered an exclusive license agreement with Exact Sciences for its colorectal cancer blood test and announced a $330M SPAC merger to go public.